Baird lowered the firm’s price target on Maravai Lifesciences to $7 from $11 and keeps an Outperform rating on the shares. The firm said they reported 3Q revenue below expectations and lowered 2023 guidance on continued customer spending caution, with management not seeing signs of a near-term recovery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRVI:
- Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023
- Maravai LifeSciences Hosts 2023 Investor R&D Day
- Maravai Lifesciences targets $700M in revenue in 2028
- Maravai Lifesciences to host Investor R&D day
- Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100
